Parexel Biotech conducting Ph IIa neurodegenerative disease trial

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/Zinkevych)
(Image: Getty/Zinkevych)

Related tags Parexel Biotech Clinical trial

AlzProtect is collaborating with Parexel Biotech to advance a Phase IIa clinical trial of its lead candidate, AZP2006, which is being developed for the treatment of a rare neurodegenerative disease.

Alzprotect is a biopharmaceutical company focused on developing drugs for the treatment of progressive supranuclear palsy (PSP) and Alzheimer's disease.

Parexel Biotech today announced that it has been selected to conduct the clinical Ph IIa development of AZP2006, Alzprotect’s flagship product.

The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have granted AZP2006 orphan drug status in the indication of PSP.

AZP2006 was previously tested in two Phase I trials and demonstrated excellent tolerability, with no adverse effects, according to the company.

Parexel Biotech’s offering will include regulatory and strategic consulting, the ability to recruit patients and conduct trials, generation of real-world evidence (RWE) leveraging internal expertise and partnerships, such as with Datavant and SHYFT Analytics, among others.

The contract research organization (CRO) launched​ the dedicated biotech division earlier this year.

Related topics Clinical Development Phase I-II

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers

Follow us

Products

View more

Webinars